Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 4/20 | 0.70 |
| ▸ | SHBG | P04278 | 5/20 | 0.59 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ESR1 | P03372 | 1/20 | 0.59 |
| ▸ | AR | P10275 | 1/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | GUSB | P08236 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CYP17A1 | P05093 | 10/20 | 0.57 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14193745 | 1.00 | G6PD (0.70) | G6PDSHBGSERPINA6LMNAESR1 | |
| SCHEMBL12153536 | 1.00 | G6PD (0.70) | G6PDSHBGSERPINA6LMNAESR1 | |
| SCHEMBL12403266 | 1.00 | G6PD (0.70) | G6PDSHBGSERPINA6LMNAESR1 | |
| SCHEMBL13420735 | 1.00 | G6PD (0.70) | G6PDSHBGSERPINA6LMNAESR1 | |
| SCHEMBL14193758 | 1.00 | G6PD (0.70) | G6PDSHBGSERPINA6LMNAESR1 | |
| SCHEMBL1126907 | 1.00 | G6PD (0.70) | G6PDSHBGSERPINA6LMNAESR1 | |
| SCHEMBL14193756 | 1.00 | G6PD (0.70) | G6PDSHBGSERPINA6LMNAESR1 | |
| SCHEMBL13420269 | 1.00 | G6PD (0.70) | G6PDSHBGSERPINA6LMNAESR1 | |
| SCHEMBL1126576 | 1.00 | G6PD (0.70) | G6PDSHBGSERPINA6LMNAESR1 | |
| SCHEMBL13642783 | 1.00 | G6PD (0.70) | G6PDSHBGSERPINA6LMNAESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360673-A1 | HAIR COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2017-12-21 | — | — | US | claimed |
| EP-3236927-A1 | HAIR COMPOSITION | Unilever PLC (GB) | 2017-11-01 | — | — | EP | claimed |
| WO-2016102177-A1 | HAIR COMPOSITION | UNILEVER PLC (GB) | 2016-06-30 | — | — | WO | claimed |
| EP-1627030-A1 | NITROGEN REJECTION FROM CONDENSED NATURAL GAS | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2006-02-22 | — | — | EP | claimed |
| US-20050085452-A1 | Process for the synthesis of pharmacologically active (z/e)-guggulsterones | LAILA IMPEX (IN) | 2005-04-21 | — | — | US | claimed |
| WO-2004104143-A1 | NITROGEN REJECTION FROM CONDENSED NATURAL GAS | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2004-12-02 | — | — | WO | claimed |
| WO-2004103376-A2 | SKIN TREATMENTS | UNILEVER PLC (GB) | 2004-12-02 | — | — | WO | claimed |
| EP-1432399-A1 | ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN | UNILEVER PLC (GB) | 2004-06-30 | — | — | EP | claimed |
| WO-2004021975-A2 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF PHARMACOLOGICALLY ACTIVE (Z/E)-GUGGULSTERONES | GOKARAJU GANGA RAJU (IN) | 2004-03-18 | — | — | WO | claimed |
| US-20030124159-A1 | Enhancing epidermal barrier development in skin | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC | 2003-07-03 | — | — | US | claimed |
| WO-2003030857-A1 | ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN | UNILEVER PLC (GB) | 2003-04-17 | — | — | WO | claimed |
| CN-107106628-B | Hair composition | 荷兰联合利华有限公司 | 2021-01-12 | — | — | CN | disclosed |
| US-10456344-B2 | Hair composition | CONOPCO, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10406091-B2 | Skin anti-ageing composition | CONOPCO, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-2788088-B1 | SKIN ANTI-AGEING COMPOSITION | UNILEVER PLC (GB) | 2019-06-19 | — | — | EP | disclosed |
| WO-2004104143-A1 | NITROGEN REJECTION FROM CONDENSED NATURAL GAS | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| EP-1432399-A1 | ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN | UNILEVER PLC (GB) | 2004-06-30 | — | — | EP | disclosed |
| WO-2004021975-A2 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF PHARMACOLOGICALLY ACTIVE (Z/E)-GUGGULSTERONES | GOKARAJU GANGA RAJU (IN) | 2004-03-18 | — | — | WO | disclosed |
| US-20030124159-A1 | Enhancing epidermal barrier development in skin | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC | 2003-07-03 | — | — | US | disclosed |
| WO-2003030857-A1 | ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN | UNILEVER PLC (GB) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085452-A1 | Process for the synthesis of pharmacologically active (z/e)-guggulsterones | CYP17A1, CYP11B1, HSD17B7 | G6PD 151/4885SHBG 118/4885SERPINA6 1014/4885 |
| US-20030124159-A1 | Enhancing epidermal barrier development in skin | NR1H2, NR1H3, RXRB | G6PD 4801/4885SHBG 1340/4885SERPINA6 573/4885 |
| US-10456344-B2 | Hair composition | GLS2, GLS, LHCGR | G6PD 3554/4885SHBG 42/4885SERPINA6 2661/4885 |
| US-20170360673-A1 | HAIR COMPOSITION | GLS2, GLS, CYP17A1 | G6PD 3507/4885SHBG 43/4885SERPINA6 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.